β2AR agonists, mainly terbutaline, have been reported to ameliorate the clinical symptoms in MG patients [3] and recently this group of medication (albuterol) was recognized to improve clinical symptoms also in patients with congenital myasthenic syndromes (CMS) [31]. The gene discussed is ADRB2; the disease is myasthenia gravis.